Anthropic Acquires Coefficient Bio to Deepen Life Sciences Push
Anthropic is acquiring Coefficient Bio, a New York-based startup, for approximately $400 million. The deal marks the AI company's latest move to establish itself as a core tool in pharmaceutical operations.
Coefficient, which has fewer than 10 employees, will join Anthropic's healthcare team. The startup has operated largely in stealth mode, with minimal public information about its platform or business focus.
Details about the transaction remain scarce. Neither company has confirmed the deal, and the timing of a close is unclear. Anthropic did not respond to requests for comment.
Building on Existing Pharma Relationships
The acquisition builds on work Anthropic started in October 2025, when it released Claude Life Sciences-a version of its AI model tailored for pharmaceutical professionals. Scientists, clinical trial coordinators, and regulatory managers at companies including Sanofi, Novo Nordisk, and AbbVie already use Claude in their operations.
Coefficient's co-founders, Nathan Frey and Samuel Stanton, both previously worked on machine learning at Roche's Genentech. Stanton currently holds a position on Anthropic's technical staff. CEO Aris Theologis previously led teams at Evozyne and Paragon Biosciences.
Pharma Doubles Down on AI Investment
The move comes as pharmaceutical companies accelerate AI adoption across drug discovery and development. Last week, Eli Lilly committed up to $2.75 billion to expand its partnership with Insilico Medicine, using the biotech's AI platform to design oral drugs. Earendil Labs raised $787 million in private funding backed by Sanofi and Pfizer for its own AI-driven drug discovery platform.
Investors increasingly view AI capability as a differentiator in biopharma. Companies using AI not just for discovery but also to communicate risk to investors are drawing the most serious investor attention, according to industry observers.
For healthcare professionals evaluating AI tools, understanding how major vendors like Anthropic are positioning themselves in biopharma can inform technology decisions. Learn more about Claude AI Courses or explore broader AI for Healthcare applications.
Your membership also unlocks:
